JP5814790B2 - デングウイルス中和抗体およびその使用 - Google Patents

デングウイルス中和抗体およびその使用 Download PDF

Info

Publication number
JP5814790B2
JP5814790B2 JP2011530592A JP2011530592A JP5814790B2 JP 5814790 B2 JP5814790 B2 JP 5814790B2 JP 2011530592 A JP2011530592 A JP 2011530592A JP 2011530592 A JP2011530592 A JP 2011530592A JP 5814790 B2 JP5814790 B2 JP 5814790B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
hmb
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011530592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504955A5 (enExample
JP2012504955A (ja
Inventor
アントニオ・ランツァヴェッキア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Original Assignee
Institute for Research in Biomedicine IRB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Research in Biomedicine IRB filed Critical Institute for Research in Biomedicine IRB
Publication of JP2012504955A publication Critical patent/JP2012504955A/ja
Publication of JP2012504955A5 publication Critical patent/JP2012504955A5/ja
Application granted granted Critical
Publication of JP5814790B2 publication Critical patent/JP5814790B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2011530592A 2008-10-13 2009-10-13 デングウイルス中和抗体およびその使用 Expired - Fee Related JP5814790B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10491108P 2008-10-13 2008-10-13
US61/104,911 2008-10-13
PCT/IB2009/007372 WO2010043977A2 (en) 2008-10-13 2009-10-13 Dengue virus neutralizing antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015112584A Division JP2016020334A (ja) 2008-10-13 2015-06-02 デングウイルス中和抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2012504955A JP2012504955A (ja) 2012-03-01
JP2012504955A5 JP2012504955A5 (enExample) 2012-11-29
JP5814790B2 true JP5814790B2 (ja) 2015-11-17

Family

ID=42102977

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011530592A Expired - Fee Related JP5814790B2 (ja) 2008-10-13 2009-10-13 デングウイルス中和抗体およびその使用
JP2015112584A Pending JP2016020334A (ja) 2008-10-13 2015-06-02 デングウイルス中和抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015112584A Pending JP2016020334A (ja) 2008-10-13 2015-06-02 デングウイルス中和抗体およびその使用

Country Status (10)

Country Link
US (1) US9073981B2 (enExample)
EP (1) EP2334700B1 (enExample)
JP (2) JP5814790B2 (enExample)
CN (2) CN102272155B (enExample)
AU (1) AU2009305113B2 (enExample)
BR (1) BRPI0914012B1 (enExample)
CA (1) CA2739551C (enExample)
MX (1) MX2011003588A (enExample)
NZ (1) NZ592054A (enExample)
WO (1) WO2010043977A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2644236T3 (es) * 2010-12-14 2017-11-28 National University Of Singapore Anticuerpo humano monoclonal con especificidad para el virus Dengue serotipo 1 E proteína y usos de la misma
WO2013035345A2 (en) * 2011-09-09 2013-03-14 Osaka University Dengue-virus serotype neutralizing antibodies
WO2013173348A1 (en) * 2012-05-14 2013-11-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Cross-reactive antibodies against dengue virus and uses thereof
WO2014025546A2 (en) 2012-08-07 2014-02-13 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
WO2015089492A2 (en) * 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
JP7078350B2 (ja) 2013-10-28 2022-05-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｄｎａ抗体構築物及びその使用方法
KR20230156146A (ko) * 2012-12-13 2023-11-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｄｎａ 항체 작제물 및 그 이용 방법
JP6154126B2 (ja) * 2012-12-20 2017-06-28 功 宮崎 検査キットおよび検査方法
SG11201507359SA (en) 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Flavivirus neutralizing antibodies and methods of use thereof
CN103396481B (zh) * 2013-07-18 2015-06-03 华南理工大学 一种二型登革热病毒ns1蛋白的重链单域抗体及其制备方法和应用
WO2015095511A2 (en) * 2013-12-20 2015-06-25 The Scripps Research Institute Functional antibodies that modulate cell death and related methods
CA2938590C (en) 2014-02-11 2023-10-17 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
SG10201807826XA (en) * 2014-02-11 2018-10-30 Massachusetts Inst Technology Novel full spectrum anti-dengue antibody
RS61000B1 (sr) * 2014-09-01 2020-11-30 Int Centre For Genetic Engineering And Biotechnology Vakcina
BR112017011556A2 (en) 2014-12-01 2018-03-06 The Trustees Of The University Of Pennsylvania methods for generating a synthetic antibody, preventing or treating a disease, treating a subject of pathogen infection and a subject with cancer, product, nucleic acid molecule, and composition.
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
SG11201707592TA (en) * 2015-03-17 2017-10-30 Agency Science Tech & Res A serotype cross-reactive, dengue neutralizing antibody and uses thereof
WO2017011495A1 (en) * 2015-07-14 2017-01-19 Vanderbilt University Engineered antibodies against dengue virus
JP7155009B2 (ja) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
TWI769185B (zh) * 2016-10-27 2022-07-01 海樂源有限公司 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物
US11249082B2 (en) 2016-10-29 2022-02-15 University Of Miami Zika virus assay systems
US20190324040A1 (en) * 2016-10-29 2019-10-24 University Of Miami Zika virus antibodies
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
KR102238183B1 (ko) 2018-05-04 2021-04-12 가톨릭대학교 산학협력단 유전자 합성을 통해 설계된 뎅기열 바이러스의 유전형 복합 ｎｓ１ 재조합 항원 및 대조군 유행성 플라비바이러스 유전형 복합 ns1 재조합 항원 풀
US11830582B2 (en) 2018-06-14 2023-11-28 University Of Miami Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
WO2020078568A1 (en) 2018-10-19 2020-04-23 Humabs Biomed Sa Antibodies and methods for treatment of lyssavirus infection
CN111320688B (zh) * 2018-12-17 2021-08-24 中国科学院天津工业生物技术研究所 一种黄病毒中和抗体、其制备方法及应用
KR102048812B1 (ko) * 2018-12-19 2019-11-26 주식회사 엠디헬스케어 뎅기 바이러스 ediii에 특이적으로 결합하는 dna 압타머 및 이의 용도
EP4153625A4 (en) * 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB819376A (en) 1956-10-20 1959-09-02 Colne Switchgear K & W Ltd Improvements in electro-magnetic overload units for electrical apparatus
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
US6300104B1 (en) 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
US7473424B2 (en) * 2003-01-31 2009-01-06 The Scripps Research Institute Anti-dengue virus antibodies and compositions
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
US7622113B2 (en) * 2003-12-08 2009-11-24 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
WO2009011941A2 (en) * 2007-04-04 2009-01-22 The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region

Also Published As

Publication number Publication date
AU2009305113B2 (en) 2015-07-16
CN102272155A (zh) 2011-12-07
CA2739551C (en) 2019-03-05
AU2009305113A1 (en) 2010-04-22
EP2334700B1 (en) 2017-09-13
EP2334700A2 (en) 2011-06-22
WO2010043977A3 (en) 2010-09-30
CN102272155B (zh) 2018-05-25
CA2739551A1 (en) 2010-04-22
US20120020957A1 (en) 2012-01-26
WO2010043977A2 (en) 2010-04-22
JP2016020334A (ja) 2016-02-04
JP2012504955A (ja) 2012-03-01
CN108610416A (zh) 2018-10-02
BRPI0914012A2 (pt) 2021-02-23
BRPI0914012B1 (pt) 2022-02-15
US9073981B2 (en) 2015-07-07
NZ592054A (en) 2013-06-28
MX2011003588A (es) 2011-10-14
CN108610416B (zh) 2022-01-14

Similar Documents

Publication Publication Date Title
US9073981B2 (en) Dengue virus neutralizing antibodies and use thereof
JP5710123B2 (ja) ヒトサイトメガロウイルス中和抗体およびその使用
KR101732056B1 (ko) 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
JP5475774B2 (ja) ヒトサイトメガロウイルス中和抗体およびその使用
CN103717617B (zh) 中和抗甲型流感病毒抗体及其用途
HK1260890B (zh) 登革热病毒中和抗体及其用途
HK1260890A1 (zh) 登革热病毒中和抗体及其用途
HK1164898A (en) Dengue virus neutralizing antibodies and uses thereof
HK1164898B (en) Dengue virus neutralizing antibodies and uses thereof
JP2014087349A (ja) ヒトサイトメガロウイルス中和抗体およびその使用
AU2013202434A1 (en) Dengue virus neutralizing antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121011

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140630

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140731

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140829

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150602

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150702

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150918

R150 Certificate of patent or registration of utility model

Ref document number: 5814790

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees